Sonic Hedgehog Signature in Pediatric Primary Bone Tumors: Effects of the GLI Antagonist GANT61 on Ewing’s Sarcoma Tumor Growth

Osteosarcoma (OS) and Ewing’s sarcoma (ES) are the most common malignant bone tumors in children and adolescents. In many cases, the prognosis remains very poor. The Sonic hedgehog (SHH) signaling pathway, strongly involved in the development of many cancers, regulate transcription via the transcrip...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2020-11, Vol.12 (11), p.3438
Main Authors: Mullard, Mathilde, Cadé, Marie, Morice, Sarah, Dupuy, Maryne, Danieau, Geoffroy, Amiaud, Jérome, Renault, Sarah, Lézot, Frédéric, Brion, Régis, Thepault, Rose Anne, Ory, Benjamin, Lamoureux, François, Corre, Isabelle, Brounais-LeRoyer, Bénédicte, Rédini, Françoise, Verrecchia, Franck
Format: Article
Language:English
Subjects:
Apoptosis
Bone cancer
Bone tumors
Caspase-3
Chemotherapy
Development and progression
Ewing's sarcoma
Gene expression
Hedgehog protein
Hedgehog proteins
Life Sciences
Ligands
Mutation
Osteosarcoma
Pediatric tumors
Physiological aspects
Sarcoma
Signal transduction
Transcription factors
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Osteosarcoma (OS) and Ewing’s sarcoma (ES) are the most common malignant bone tumors in children and adolescents. In many cases, the prognosis remains very poor. The Sonic hedgehog (SHH) signaling pathway, strongly involved in the development of many cancers, regulate transcription via the transcriptional factors Gli1-3. In this context, RNAseq analysis of OS and ES cell lines reveals an increase of some major compounds of the SHH signaling cascade in ES cells, such as the transcriptional factor Gli1. This increase leads to an augmentation of the transcriptional response of Gli1 in ES cell lines, demonstrating a dysregulation of Gli1 signaling in ES cells and thus the rationale for targeting Gli1 in ES. The use of a preclinical model of ES demonstrates that GANT61, an inhibitor of the transcriptional factor Gli1, reduces ES primary tumor growth. In vitro experiments show that GANT61 decreases the viability of ES cell, mainly through its ability to induce caspase-3/7-dependent cell apoptosis. Taken together, these results demonstrates that GANT61 may be a promising therapeutic strategy for inhibiting the progression of primary ES tumors.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers12113438